MYO1G

Across TCGA pan-cancer cohorts, MYO1G RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of MYO1G’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where MYO1G RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MYO1G is over-expressed in tumor, although a few such as LUSC and LUAD show the opposite, repressed pattern.

KIRC, HNSC, and THCA are the cancer types where MYO1G tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MYO1G RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	IV	+2.209	<.001	12	view →
HNSC	All	III,IV	+1.198	<.001	11	view →
THCA	Male	III,IV	+2.217	<.001	10	view →
KIRP	All	III,IV	+0.988	<.001	9	view →
LUSC	Female	All	−1.604	<.001	7	view →
STAD	All	II,III,IV	+1.040	.001	7	view →
BRCA	All	All	+0.485	<.001	6	view →
LUAD	Male	All	−0.786	.012	2	view →
PRAD	All	All	+0.621	<.001	2	view →
LIHC	Female	II,III,IV	+0.448	.017	2	view →
ESCA	All	All	+1.099	.009	1	view →
CHOL	All	All	+0.913	.017	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

MYO1G–KIRC

Open the KIRC breakdown →